Cargando…

Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives

Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics, i.e., colistin, tobramycin, aztreonam lysine and levofloxacin, are used as maintenance treatment for CF patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taccetti, Giovanni, Francalanci, Michela, Pizzamiglio, Giovanna, Messore, Barbara, Carnovale, Vincenzo, Cimino, Giuseppe, Cipolli, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004710/ https://www.ncbi.nlm.nih.gov/pubmed/33810116 http://dx.doi.org/10.3390/antibiotics10030338

Ejemplares similares

Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice
por: Terlizzi, Vito, et al.
Publicado: (2021)

Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society
por: Colombo, Carla, et al.
Publicado: (2021)

ePS4.07 COVID-19 early vaccination campaign in Italian cystic fibrosis (CF) patients: the experience of the Italian Society for the Study of Cystic Fibrosis (SIFC)
por: Lucca, F., et al.
Publicado: (2022)

Clinical characteristics and outcome of SARS –CoV-2 infection in patients with cystic fibrosis managed at home
por: Terlizzi, V., et al.
Publicado: (2022)

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study
por: Carnovale, Vincenzo, et al.
Publicado: (2022)

SARS-CoV-2 infection in cystic fibrosis: A multicentre prospective study with a control group, Italy, February-July 2020
por: Colombo, Carla, et al.
Publicado: (2021)

Cystic fibrosis in Tuscany: evolution of newborn screening strategies over time to the present
por: Botti, Matteo, et al.
Publicado: (2021)

Extensive CFTR Gene Analysis Revealed a Higher Occurrence of Cystic Fibrosis Transmembrane Regulator-Related Disorders (CFTR-RD) among CF Carriers
por: Esposito, Maria Valeria, et al.
Publicado: (2020)

P163 Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany
por: Dolce, D., et al.
Publicado: (2021)

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities
por: Nichols, Dave P., et al.
Publicado: (2019)

Use of inhaled antibiotics among Danish patients with cystic fibrosis
por: Møller, Rikke, et al.
Publicado: (2022)

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
por: Terlizzi, Vito, et al.
Publicado: (2021)

Salivary Cytokines and Airways Disease Severity in Patients with Cystic Fibrosis
por: Castaldo, Alice, et al.
Publicado: (2020)

P134 SARS-CoV-2 infection in cystic fibrosis during the first pandemic wave in Italy: a multi-centre prospective study with a control group
por: Colombo, C., et al.
Publicado: (2021)

Mortality rate of patients with cystic fibrosis on the waiting list and within one year after lung transplantation: a survey of Italian CF centers
por: Borchi, Beatrice, et al.
Publicado: (2018)

Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
por: Volpi, Sonia, et al.
Publicado: (2022)

The emergence of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients on inhaled antibiotics
por: AbdulWahab, Atqah, et al.
Publicado: (2017)

Inhaled Biologicals for the Treatment of Cystic Fibrosis
por: Sala, Valentina, et al.
Publicado: (2019)

Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index
por: Terlizzi, Vito, et al.
Publicado: (2022)

Is cellular senescence involved in cystic fibrosis?
por: Bezzerri, Valentino, et al.
Publicado: (2019)

Risk of Development of Resistance in Patients with Non-Cystic Fibrosis Bronchiectasis Treated with Inhaled Antibiotics
por: Regan, Kate H., et al.
Publicado: (2018)

Inhaled antibiotics therapy for stable non-cystic fibrosis bronchiectasis: a meta-analysis
por: Xu, Meng-Jiao, et al.
Publicado: (2020)

Association of Oxygen Therapy with the Natural Disease Progression of Cystic Fibrosis: A Multi-State Model of the European Cystic Fibrosis Society Patient Registry
por: Gambazza, Simone, et al.
Publicado: (2023)

Employment Status and Work Ability in Adults with Cystic Fibrosis
por: Leso, Veruscka, et al.
Publicado: (2021)

Microbiology of airway disease in a cohort of patients with Cystic Fibrosis
por: Lambiase, Antonietta, et al.
Publicado: (2006)

Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators
por: Francalanci, Michela, et al.
Publicado: (2023)

A New Method to Improve the Clinical Evaluation of Cystic Fibrosis Patients by Mucus Viscoelastic Properties
por: Tomaiuolo, Giovanna, et al.
Publicado: (2014)

Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future
por: Perikleous, Evanthia P., et al.
Publicado: (2023)

Gene Therapy for Cystic Fibrosis: Recent Advances and Future Prospects
por: Lomunova, M. A., et al.
Publicado: (2023)

Does cystic fibrosis constitute an advantage in COVID-19 infection?
por: Bezzerri, Valentino, et al.
Publicado: (2020)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
por: Elson, Elizabeth Claire, et al.
Publicado: (2019)

Comparison between Gibson–Cooke and Macroduct Methods in the Cystic Fibrosis Neonatal Screening Program and in Subjects Who Are Cystic Fibrosis Screen-Positive with an Inconclusive Diagnosis
por: Dolce, Daniela, et al.
Publicado: (2023)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Role of inhaled antibiotics in children and adolescents with cystic fibrosis: Experience from the tertiary care center
por: Aziz, Danish Abdul, et al.
Publicado: (2022)

Lipidomic alterations in human saliva from cystic fibrosis patients
por: Caterino, Marianna, et al.
Publicado: (2023)

The Diagnosis of Cystic Fibrosis in Adult Age. Data from the Italian Registry
por: Padoan, Rita, et al.
Publicado: (2021)

Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects
por: Wan, Qianyu, et al.
Publicado: (2023)

In Vitro Inhibition of Neutrophil Elastase Activity by Inhaled Anti-Pseudomonas Antibiotics Used in Cystic Fibrosis Patients
por: Hector, Andreas, et al.
Publicado: (2010)

The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis
por: Dhand, Rajiv
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9c9m3jgqg2n0205smfjvfnv1f6